News

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...
WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.
Integrating HIV and sexual health care is essential for improving outcomes, but global stigma, funding cuts—especially the defunding of USAID—and structural barriers like limited access and political ...
Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating patient-focused innovations for HIV prevention and treatment.
Purpose Adolescents living with HIV (ALHIV) are a priority population for achieving global HIV prevention and treatment targets but experience poorer outcomes than adults. Long-term follow-up is ...
In the ongoing fight against HIV, scientists have taken a new step toward long-term control of the virus. Researchers have ...
Innovative, nontoxic molecules developed by a research team at the Institut national de la recherche scientifique (INRS) ...
The Australian researchers developed a novel mRNA-based technology capable of reaching the white blood cells where HIV lies ...
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah biochemist whose discoveries helped make the drug happen worries government cuts ...
Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.